Injective is making a numbers driven pitch to crypto investors. Its revenue to fully dilution valuation (FDV) ratio now leads the major blockchain platforms shown in the year 2026 year to date comparison, putting INJ ahead of better known rivals on this particular metric. The catch? A strong ratio can support a valuation argument, but it doesn’t guarantee a rising token price.

Injective Takes the Lead on Revenue to FDV

The chart places Injective at a revenue to FDV ratio of 0.95, ahead of Solana at 0.83 and Arbitrum 0.78. That’s more than 20% above Arbitrum and ahead of Solana.

The gap looks even wider against Ethereum, at 0.11, and both Sui and Avalanche, each shown at 0.08. Injective’s ratio is over eight times Ethereum’s and more than ten times those two networks’ figures.

Those numbers make Injective stand out in this comparison. Revenue relative to fully diluted valuation offers one way to assess how much onchain revenue a network generates against its potential token valuation. Still, one metric can’t tell the whole story about risk or future performance.

Injective now leads all major blockchains by revenue to fully diluted market cap.

→ Ahead of Solana
→ Over 20% ahead of Arbitrum
→ Over 8x Ethereum
→ Over 10x Sui and Avalanche

Revenue / FDV is one of the clearest measures of whether a network’s valuation is backed by real… pic.twitter.com/MLLzOCzqJP

— Injective 🥷 (@injective) October 15, 2026

The Buyback Mechanism Gives INJ Another Angle

Injective’s pitch goes beyond the chart. Onchain revenue flows into the INJ Community BuyBack, which permanently removes INJ tokens from circulation every month.

That creates a potential supply reduction mechanism tied to network revenue. But the effect on market price depends on more than token removals alone, the figures provided don’t quantify the buyback’s price impact.

Future Growth Still Has to Deliver

Injective expects revenue to accelerate as it onboards new tokenization initiatives and launches additional products in the coming months. If that happens, the revenue story could strengthen.

For now, the Injective revenue to FDV lead is a compelling snapshot, not a guarantee. Investors will need to watch whether new products generate sustained revenue and whether the buyback translates into meaningful token value over time.